Literature DB >> 2788010

Antibodies to Ro/SSA detected by ELISA: correlation with clinical features in systemic scleroderma.

S Bell1, T Krieg, M Meurer.   

Abstract

Anti-Ro/SSA antibodies were determined by a newly developed enzyme-linked immunosorbent assay in serum specimens from 114 patients with systemic scleroderma in order to examine the relationship between Ro/SSA antibodies and clinical subsets of scleroderma. Sera of 42 patients (37%) were positive for Ro/SSA antibodies. Clinical investigations, including Schirmer's test and enzymatic profiles, demonstrated that 60% (16 of 27) of scleroderma patients with sicca syndrome and 63% (10 of 16) with polymyositis (PM) were Ro/SSA positive. In these patients there was a significant association between Ro/SSA antibodies and rheumatoid factor. HLA-antigens DR2, DR3 and B8 showed an increased frequency in anti-Ro/SSA positive patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788010     DOI: 10.1111/j.1365-2133.1989.tb01397.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Hand-genital transmission of genital warts? An analysis of prevalence data.

Authors:  C K Fairley; N J Gay; A Forbes; M Abramson; S M Garland
Journal:  Epidemiol Infect       Date:  1995-08       Impact factor: 2.451

2.  Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis.

Authors:  G R Harvey; S Butts; A L Rands; Y Patel; N J McHugh
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

3.  Ocular findings in patients with systemic sclerosis.

Authors:  Beatriz de A F Gomes; Marcony R Santhiago; Priscilla Magalhães; Newton Kara-Junior; Mário N L de Azevedo; Haroldo V Moraes
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 4.  The clinical relevance of autoantibodies in scleroderma.

Authors:  Khanh T Ho; John D Reveille
Journal:  Arthritis Res Ther       Date:  2003-02-12       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.